The COVID-19 pandemic has not only challenged the healthcare industry globally but also fast-tracked the adoption of technology across crucial sectors. Insilico Medicine, a pioneer in AI-driven drug discovery, shares how their innovation is improving the quality of healthcare.

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.

The company integrates two business models: One provides AI-powered drug discovery services and software through its Pharma.AI platform. Another is developing internal drug pipelines for novel and previously undruggable targets.

As a pioneer and leader in the industry, Insilico Medicine has reached several milestones in the past year. In February, the company demonstrated the first case of AI identifying a novel target for idiopathic pulmonary fibrosis and generating novel molecules for that novel target, completing the preclinical experiments required to nominate a potential candidate in under 18 months. In November, Insilico Medicine initiated the first-in-human study of the company’s drug candidate.

The company believes this is a significant milestone in the history of AI-powered drug discovery because, to their knowledge, the drug candidate is the first-ever AI-discovered novel molecule based on an AI-discovered novel target.

Insilico Medicine also disclosed a series of collaborations. Some of the biggest names in the industry, such as Pfizer, Teva, Taisho, collaborated with Insilico Medicine for target discovery. Seven out of the top twenty pharmaceutical companies used their chemistry software.

Johnson and Johnson, Astellas, and many others also partnered with Insilico Medicine on drugging challenging targets. On top of that, Insilico Medicine also partnered with protein degradation pioneers Arvinas, PAQ.

According to Insilico Medicine’s management, nobody in the pharma world would deny that AI will make a very substantial impact in healthcare and that the company believes they are just scratching the surface. Insilico Medicine hopes to extend healthy life for everyone on the planet by decreasing the failure rates, reducing the price of medicines, and improving the quality of healthcare.

For more information, visit